查看“戈利木单抗”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[戈利木单抗]]</strong>（<strong>[[Golimumab]]</strong>，商品名：<strong>[[欣普尼]]</strong>）是一种全人源化抗<strong>[[肿瘤坏死因子α]]</strong>（<strong>[[TNF-α]]</strong>）单克隆抗体（[[IgG1]]κ型）。作为新一代[[TNF-α]]抑制剂，它通过转基因小鼠技术制备，能够以极高的亲和力和稳定性同时中和可溶型及膜结合型[[TNF-α]]。[[戈利木单抗]]在临床上主要用于治疗多种慢性免疫介导的炎症性疾病，包括<strong>[[类风湿关节炎]]</strong>、<strong>[[强直性脊柱炎]]</strong>、<strong>[[银屑病关节炎]]</strong>及<strong>[[溃疡性结肠炎]]</strong>。其独特的药代动力学特性支持每月一次的[[皮下注射]]给药，显著提升了患者的长期依从性。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[戈利木单抗]]</div>
            <div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">[[Golimumab]] / [[欣普尼]] · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 20px; text-align: center; background-color: #f8fafc;">
                <div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;">
                    <div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[戈利木单抗]]抗体分子三维结构</div>
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[TNF-α]] / [[TNFSF2]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]]ID</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">7124([[TNF]])</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[全人源单克隆抗体]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[CAS]]号</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">476181-74-5</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">约 150 kDa</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药方式</th>
                    <td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[皮下注射]] (每月一次)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发厂商</th>
                    <td style="padding: 12px; color: #0f172a;">[[Janssen]] (杨森/强生)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：深度拦截促炎信号</h2>
    
    <p style="margin: 15px 0; text-align: justify;">
        [[戈利木单抗]]的作用机制基于对[[炎症反应]]中枢介质[[TNF-α]]的精准中和。由于其“全人源”特性，其[[免疫原性]]显著低于[[英夫利昔单抗]]：
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>高亲和力结合：</strong>[[戈利木单抗]]与[[TNF-α]]结合后，通过空间阻碍效应防止其与受体[[TNFR1]]或[[TNFR2]]结合。这种阻断动作能迅速下调下游<strong>[[NF-κB]]</strong>和<strong>[[MAPK]]</strong>信号通路的活性。</li>
        <li style="margin-bottom: 12px;"><strong>调节促炎因子网络：</strong>使用该药可显著降低循环中[[白细胞介素6]]（[[IL-6]]）、[[细胞间粘附分子1]]（[[ICAM-1]]）以及血管内皮生长因子（[[VEGF]]）的水平，从而抑制白细胞向炎症部位的募集。</li>
        <li style="margin-bottom: 12px;"><strong>靶细胞调节：</strong>除了中和游离因子外，[[戈利木单抗]]还能结合表达膜型[[TNF-α]]的细胞（如活化的单核细胞），诱导局部免疫调节作用。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用矩阵：欣普尼的关键研究</h2>

    <div style="overflow-x: auto; margin: 25px auto; width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究项目</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">目标疾病</th>
                <th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">临床意义</th>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GO-FORWARD]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[类风湿关节炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[MTX]]应答不佳患者，联合治疗显著提升[[ACR20/50]]。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GO-RAISE]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[强直性脊柱炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">有效改善[[BASDAI]]评分，显著控制脊柱MRI炎症信号。</td>
            </tr>
            <tr>
                <td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[PURSUIT研究]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">[[溃疡性结肠炎]]</td>
                <td style="padding: 8px; border: 1px solid #cbd5e1;">诱导并维持肠道黏膜愈合，减少长期激素依赖。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：安全筛查与长程管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        [[戈利木单抗]]的规范化应用需严格平衡抗炎药效与全身免疫监视风险：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>感染排查前置：</strong>应用前必须进行[[结核分枝杆菌]]（[[T-SPOT]]）和[[乙肝]]（[[HBV]]）筛查。[[TNF抑制剂]]可导致潜伏性结核复燃或乙肝病毒再激活。</li>
        <li style="margin-bottom: 12px;"><strong>精准剂量分层：</strong>成人通常为每月50mg。对于体重超过100kg且应答不完全的RA患者，临床考虑增加至100mg，但需密切监测副作用。</li>
        <li style="margin-bottom: 12px;"><strong>免疫原性监控：</strong>虽然风险较低，但仍需警惕[[抗药抗体]]（[[ADA]]）的产生。对于疗效衰减的患者，需进行[[治疗药物监测]]（[[TDM]]）。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <ul style="margin: 0; padding-left: 20px; color: #334155;">
            <li style="margin-bottom: 8px;"><strong>[[TNF-α]]：</strong>全身性炎症的关键开关，戈利木单抗的唯一靶向分子。</li>
            <li style="margin-bottom: 8px;"><strong>[[全人源化抗体]]：</strong>完全由人类基因序列产生的抗体，降低了抗抗体反应风险。</li>
            <li style="margin-bottom: 8px;"><strong>[[阿达木单抗]] (Humira)：</strong>首个全人源 [[TNF]] 抑制剂，戈利木单抗在其基础上优化了亲和力与给药频率。</li>
            <li style="margin-bottom: 8px;"><strong>[[欣普尼智能注射器]]：</strong>专为患者自用设计的预充式注射笔。</li>
        </ul>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Smolen JS, et al. (2009).</strong> <em>Golimumab in patients with active rheumatoid arthritis after treatment with TNF-α inhibitors.</em> <strong>[[The Lancet]]</strong>. 374:210-221.[Academic Review]<br>
            <span style="color: #475569;">[权威点评]：该研究确立了戈利木单抗在TNF经治失败后的补救地位。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Inman RD, et al. (2008).</strong> <em>Efficacy and safety of golimumab in patients with active ankylosing spondylitis.</em> <strong>[[Arthritis & Rheumatism]]</strong>.<br>
            <span style="color: #475569;">[核心价值]：提供了戈利木单抗在强直性脊柱炎领域长达5年的安全性追踪数据。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            [[戈利木单抗]] ([[欣普尼]]) 诊疗生态 · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联因子</td>
                <td style="padding: 10px 15px; color: #334155;">[[TNF-α]]•[[CRP]]•[[ESR]]•[[IL-17]](平行通路)</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗药物</td>
                <td style="padding: 10px 15px; color: #334155;">[[阿达木单抗]]•[[依那西普]]•[[托珠单抗]]•[[司库奇尤单抗]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[Janssen]]•[[FDA]]•[[NMPA]]•[[EULAR]]</td>
            </tr>
            <tr>
                <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td>
                <td style="padding: 10px 15px; color: #334155;">[[针对儿童青少年IA的临床研究]]•[[戈利木单抗联用生物类似药的转化]]•[[重症葡萄膜炎的探索治疗]]</td>
            </tr>
        </table>
    </div>

</div>